三阳性乳腺癌与Her-2过表达型乳腺癌的预后分析  

Prognostic analysis of triple positive breast cancer and Her-2 overexpressing breast cancer

作　　者：张欣然 韩正祥 ZHANG Xinran;HAN Zhengxiang(Department of Oncology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221002,China)

机构地区：[1]徐州医科大学附属医院肿瘤科,江苏徐州221002

出　　处：《徐州医科大学学报》2024年第5期313-318,共6页Journal of Xuzhou Medical University

基　　金：国家自然科学基金(82171762);江苏省卫健委科研项目(LGY2020006)。

摘　　要：目的通过探讨三阳性乳腺癌与人表皮生长因子受体2(human epidermal growth factor receptor-2,Her-2)过表达型乳腺癌的临床病理特征及预后的差异,揭示这2种亚型的异质性,以期为这2种乳腺癌诊疗方案的选择提供数据支撑。方法收集2016年7月至2022年9月在徐州医科大学附属医院诊断和收治的三阳性乳腺癌患者179例,Her-2过表达型乳腺癌患者161例,采用病例对照的方法,对其临床资料进行回顾性分析,研究其临床病理特征及预后状况。结果与Her-2过表达型乳腺癌相比,三阳性乳腺癌发病年龄更早,较常发生于绝经前的患者,TNM分期较晚,更容易侵犯脉管和神经,Ki-67(proliferating cell nucleus antigen 67,Ki67)多为高表达;三阳性乳腺癌患者的总生存期(overall survival,OS)与无进展生存期(progression-free survival,PFS)均高于Her-2过表达型。结论三阳性乳腺癌患者的预后优于Her-2过表达型,但由于其靶向治疗与内分泌治疗存在交叉作用,具有耐药性的弊端,需要进一步探究。Objective To investigate the differences in clinicopathological characteristics and prognosis between triple positive breast cancer and human epidermal growth factor receptor-2(Her-2)overexpressing breast cancer,and to reveal the heterogeneity of these two subtypes,in order to provide data support for the selection of diagnostic and treatment options for these two types of breast cancer.Methods A total of 179 patients who were diagnosed with triple positive breast cancer and 161 patients with Her-2 overexpressing breast cancer in the Affiliated Hospital of Xuzhou Medical University from July 2016 to September 2022 were selected.Their clinical data were retrospectively analyzed using the case-control approach,in order to investigate their clinicopathological characteristics and prognosis.Results Compared with Her-2 overexpressing breast cancer,triple positive breast cancer had an earlier age of onset,and occurred more frequently in premenopausal patients,with late TNM stages,which was easy to invade the vasculature and nerves,and showed high expression of proliferating cell nucleus antigen 67(Ki67).The overall survival(OS)and progression-free survival(PFS)were higher in triple positive breast cancer patients than those in Her-2 overexpression patients.Conclusions Patients with triple positive breast cancer show superior prognosis to those with Her-2 overexpression.However,it has the disadvantage of drug resistance due to the cross-talk between its targeted therapy and endocrine therapy,which needs to be further explored.

关 键 词：三阳性乳腺癌 Her-2过表达型乳腺癌 临床病理特征 预后分析 

分 类 号：R737.9[医药卫生—肿瘤]